Global
中文 English
Search

快速链接
< back

To be the most open, innovative and reliable pharmaceutical service platform in the world

To be the most open, innovative and reliable pharmaceutical service platform in the world

Porton Profile
Global Presence
Corporate Culture
Contact Us

Who We Are

With over 3000 customer-centric employees, operations and commercial offices across the US, EU and China, Porton Pharma Solutions provides global pharmaceutical companies with innovative, reliable and end-to-end process R&D and manufacturing services across small molecule APIs, dosage forms and biologics.


Our Process Technology Centers and WHO/USFDA/EMA/PDMA/NMPA-inspected Manufacturing Facilities feature state-of-the-art equipment, highly flexible cGMP-compliant production assets, plus over 1200 highly skilled scientists and process engineers, all backed by a proven program management system dedicated to seamlessly delivering successful outcomes for your unique project requirements. 


We are committed to be the most open, innovative and reliable pharmaceutical service platform in the world and Enabling public’s early access to good medicines. We constantly strive for excellence, and have been recognized through awards by industry forums and global pharmaceutical companies for our process innovation, supply chain performance and compliance with global Quality and EHS standards. By efficiently advancing development and enabling commercialization of multiple high-impact medicines, Porton is proud to have earned the trust of some of the world’s leading and most innovative pharmaceutical companies and many biotechnology companies across the US, EU and Asia. 

USD489Million

2021 Revenues

50%+

yoy （Revenues）

4000

Employees

5

Regulatory Inspections of USFDA, PMDA, EMA and NMPA

> 300

Global Client QA Audits

> 80

Global Client EHS Audits

USD 489 Million

2021 Revenues

50%+

yoy （Revenues）

4000

Employees

5

Regulatory Inspections of USFDA, PMDA, EMA and NMPA

> 300

Global Client QA Audits

> 80

Global Client EHS Audits

Our Journey to Excellence

2020

Porton's 15th anniversary, development has entered an important milestone

Suzhou Porton fully started operations, focusing on gene and cell therapy services

porton Shanghai Zhangjiang Preparation R&D Center starts operation

Held the China New Drug CMC Forum and started the first year of brand building

Join hands with XtaLPi Technology to start drug research and development + AI exploration

2019

Successful EMA Audit Received at Porton’s Changshou Manufacturing Facility 

2nd Successful USFDA Audit Received at Porton’s Changshou Manufacturing Facility

Awarded "Top 20 CRO Enterprises in China – 2019”

Launched Drug Product CDMO Unit [Porton Pharmaceutical Co., Ltd] to broaden our service offering to global pharmaceutical companies

2018

Launched Exclusive Technology Partnership with Codexis Inc. to Harness the Power of Bio-catalysis for Pharmaceutical Synthesis

Porton Fine Chemicals Ltd. renamed Porton Pharma Solutions Ltd.

Launched Biologics CDMO Unit [Suzhou Porton Biologics Ltd] to bring cutting-edge development solutions for Gene and Cell Therapies production


2017

Acquired J-star Research Inc. (NJ, USA) to provide high-efficiency, integrated process chemistry and cGMP manufacturing services to US customers 

Launched New Global Corporate Headquarters & Process Technology Center in Chongqing, China 

PMDA Audit Successfully Received at Porton’s Changshou Manufacturing Facility 

2015

Successfully Received USFDA Audit at Porton’s Changshou Manufacturing Facility

2014

Porton (Stock code: 300363) was officially listed on the GEM (Growth Enterprise Market) of SZSE (Shenzhen Stock Exchange) on January 29, 2014

2013

Awarded “Leading CMO 2012” by Life Science Magazine

Successfully Received 1st USFDA Audit with Zero 483 at Porton’s Chongqing Facility

2009

Initiated Porton-up Program in Collaboration with Janssen (a unit of Johnson & Johnson) 

Successfully Received 1st cGMP Quality Audit by a Global Pharmaceutical Company 

2006

Launched 1st Manufacturing Facility in Changshou [Chongqing, China]

Established Process R&D Centers in Chongqing & Chengdu, China

2005

Porton Launches as a CMO with Global Ambitions

Corporate Social Responsibility

We are committed to helping our global customers efficiently develop high-impact and life-saving medicines, while sustainably and ethically building our business. Our social responsibility philosophy is Enabling public’s early access to good medicines; ensuring the health and well-being of our employees and communities; and emphasizing ethics and transparency in our dealings with all stakeholders.

Family Site

Legal Notices About Porton Investor Relations

Fangzheng Avenue, Shuitu, Beibei District, Chongqing, China.

Copyright © 2020 Porton Group. DIGITAL BY VTHINK

渝ICP备11005917号-1

渝公网安备 50010902001378号